Isracann Biosciences Inc.
ISCNF · OTC
5/31/2022 | 5/31/2021 | 5/31/2020 | 5/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.04 | 0.03 | -0.00 |
| FCF Yield | -18.67% | -12.82% | -26.27% | -60.77% |
| EV / EBITDA | -3.84 | -6.52 | -3.37 | -0.19 |
| Quality | ||||
| ROIC | -75.34% | -121.56% | -41.97% | -36.93% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.37 | 0.17 | 0.43 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 58.65% | 61.10% | -246.66% | 64.73% |
| Safety | ||||
| Net Debt / EBITDA | 0.09 | 0.41 | 0.35 | 0.79 |
| Interest Coverage | -169.07 | -34.27 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.19 | 0.00 |
| Cash Conversion Cycle | -2,677.12 | -3,979.95 | -7,666.80 | -7,608.16 |